Details for Patent: 8,685,980
✉ Email this page to a colleague
Which drugs does patent 8,685,980 protect, and when does it expire?
Patent 8,685,980 protects KISQALI and KISQALI FEMARA CO-PACK (COPACKAGED) and is included in two NDAs.
This patent has sixty-one patent family members in forty-eight countries.
Summary for Patent: 8,685,980
| Title: | Pyrrolopyrimidine compounds and their uses |
| Abstract: | The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein. ##STR00001## |
| Inventor(s): | Besong; Gilbert Ebai (Bad Duerkheim, DE), Brain; Christopher Thomas (North Reading, MA), Brooks; Clinton Alan (Smyrna, GA), Congreve; Miles Stuart (Royston, GB), Dagostin; Claudio (Cambridge, GB), He; Guo (Lexington, MA), Hou; Ying (Belmont, MA), Howard; Steven (Cambridge, GB), Li; Yue (Shanghai, CN), Lu; Yipin (Dublin, CA), Mortenson; Paul Neil (Cambridge, GB), Smith; Troy D. (Nashua, NH), Sung; Moo Je (Belmont, MA), Woodhead; Steven John (San Diego, CA), Wrona; Wojciech (Waltham, MA), Lagu; Bharat (Acton, MA) |
| Assignee: | Novartis AG (Basel, CH) Astex Therapeutics, Ltd. (Cambridge, GB) |
| Application Number: | 13/060,154 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,685,980 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
Drugs Protected by US Patent 8,685,980
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | KISQALI | ribociclib succinate | TABLET;ORAL | 209092-001 | Mar 13, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
| Novartis | KISQALI FEMARA CO-PACK (COPACKAGED) | letrozole; ribociclib succinate | TABLET;ORAL | 209935-001 | May 4, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,685,980
| PCT Information | |||
| PCT Filed | August 20, 2009 | PCT Application Number: | PCT/EP2009/060793 |
| PCT Publication Date: | February 25, 2010 | PCT Publication Number: | WO2010/020675 |
International Family Members for US Patent 8,685,980
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 073116 | ⤷ Try a Trial | |||
| Argentina | 111763 | ⤷ Try a Trial | |||
| Australia | 2009284098 | ⤷ Try a Trial | |||
| Brazil | PI0917791 | ⤷ Try a Trial | |||
| Canada | 2734802 | ⤷ Try a Trial | |||
| Chile | 2011000306 | ⤷ Try a Trial | |||
| China | 102186856 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
